Stereotaxis shared its third-quarter results, showing $8.9 million in sales, up 20% from last year.

Nov 10, 2026, 5:40 PM ETResultsRead the original at Benzinga

Neutral

Stereotaxis' sales rose 20% to $8.9 million as system sales grew, but catheter shortages limited recurring sales and it lost $6.5 million. Note funding supports operations, but higher costs and continued losses leave the report mixed.

STXS · Stereotaxis

AI read · Neutral

The AI's read

New systems are starting to sell, and Genesis X's easier installation could help more hospitals use Stereotaxis robots. But catheter shortages limited repeat sales, costs rose after the Robocath purchase, and Stereotaxis still lost money. Note funding supports operations, but the report shows both progress and continuing difficulties.

Get alerts for STXS

Follow Stereotaxis (STXS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for STXS

Free on the App Store and Google Play, or on the web.